

## DAFTAR PUSTAKA

1. Department of Health Hong Kong. Statistics of Cervical Cancer. 2017:1-3
2. Hillemanns P, Soergel P, Hertel H, Jentschke M. Epidemiology and Early Detection of Cervical Cancer. *Oncol Res Treat.* 2016;39(9):501-6.
3. Negrin LGC. Epidemiology of Cervical Cancer in Latin America. *Ecancermedicallscience.* 2015;9:1-14.
4. WHO. Cancer Country Profiles 2014 – Indonesia. 2014.
5. Agustina DR, Nurcahyanti. Cervical Cancer : The Case in Indonesia and Natural Product- Based Therapy. *J Cancer Biol Res.* 2016;4:1-7.
6. ICO/IARC HPV Information Centre. Human Papillomavirus and Related Diseases in Asia. *HPV Inf Cent.* 2018;1-155.
7. Kementerian Kesehatan Republik Indonesia. Data dan Informasi Kesehatan. 2017.
8. Yanti YN. Gambaran Faktor Resiko Kejadian Kanker Serviks di RSUP Dr. M. Djamil Padang. 2018.
9. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Kanker Serviks. Kom Penanggulangan Kanker Nas.2017:13.
10. Achmadi, Askandar B, Suhatno. Karakteristik Penderita Kanker Serviks 2006-2010 di RSUD dr. Soetomo. *Maj Obstet Ginekol.* 2011;19:128-33.
11. Khatun S, Ferdous N, Sharmin F, Ferdous J, Goodman A. Role of Neoadjuvant Chemotherapy in Treatment of Cervical Cancer: A Case Series of Thirty-Eight Patients Treated at Bangabandhu Sheikh Mujib Medical University in Dhaka, Bangladesh. *Open J Obstet Gynecol.* 2018;08:446-55.
12. American Cancer Society. Treatment Options for Cervical Cancer, by Stage. 2016. <https://www.cancer.org/cancer/cervical-cancer/treating/by-stage.html>. - Diakses Juni 2018.
13. Santosa C, Askandar B. Keberhasilan Kemoterapi Neoajuvan Cisplatin-Vincristine-Bleomycin dan Paclitaxel-Carboplatin Ditinjau dari Penilaian Operabilitas Kanker Serviks Stadium IIB. *Maj Obstet Ginekol.* 2011;19(3).
14. Lapresa M, Parma G, Portuesi R, Colombo N. Neoadjuvant Chemotherapy in Cervical Cancer: An update. *Expert Rev Anticancer Ther.* 2015;15(10):1171-81.
15. Sardi J, Sananes C, Giaroli A, et al. Results of A Prospective Randomized Trial with Neoadjuvant Chemotherapy in Stage IB, Bulky, Squamous

Carcinoma of The Cervix. *Gynecol Oncol.* 1993;49:156–65.

16. Iwata T, Miyauchi A, Suga Y, et al. Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer. 2016;28(11):235-40.
17. Onofrio AD, Gandolfi A. Chemotherapy of Vascularised Tumours : Role of Vessel Density and the Effect of Vascular ” Pruning ” to Cite. 2011;1-29.
18. Kyung MS, Kim HB, Seoung JY, et al. Tumor Size and Lymph Node Status Determined by Imaging are Reliable Factors for Predicting Advanced Cervical Cancer Prognosis. *Oncol Lett.* 2015;9(5):2218-24.
19. Shen Y, Yang L, Wang Z. Treatment of Early Bulky Cervical Cancer with Neoadjuvant Paclitaxel, Carboplatin and Cisplatin Prior to Laparoscopical Radical Hysterectomy and Pelvic Lymphadenectomy. *Oncol Lett.* 2012;3(3):641-5.
20. Marth C, Sundfor K, Kaern J, et al. Long-term Follow-up of Neoadjuvant Cisplatin and 5-Fluorouracil Chemotherapy in Bulky Squamous Cell Carcinoma of the Cervix. 2009;38(4):517-20.
21. Darmawati. Kanker Serviks Wanita Usia Subur. *Idea Nursing Journal.* 2008;1: 9-14.
22. Mwaka AD, Orach CG, Were EM, Lyratzopoulos G, Wabinga H, Roland M. Awareness of Cervical Cancer Risk Factors and Symptoms: Cross-Sectional Community Survey in Post-Conflict Northern Uganda. *Heal Expect.* 2016;19(4):854-67.
23. Rasjidi I. Epidemiologi Kanker Serviks. *Indonesian Journal of Cancer.* 2009;3:103-8.
24. Hidayat E, Hasibuan D.H.S, Fitriyati Y. Hubungan Kejadian Kanker Serviks dengan Jumlah Paritas di RSUD Dr. Moewardi Tahun 2013. *Jurnal Kedokteran dan Kesehatan Indonesia.* 2013;6:128-36.
25. Wulandari V. Hubungan Faktor Risiko Penggunaan Kontrasepsi Oral. *J Berk Epidemiologi.* 2016;4(3):432-42.
26. Lax S Histopathology of Cervical Precursor Lesions and Cancer. *Acta Dermatoven APA.* 2011;20:125-33.
27. Deverakonda A, Gupta N. Diagnosis and Treatment of Cervical Cancer: A Review. *J Nurs Heal Sci.* 2016;2(3):1-11.
28. Bosch FX, Muñoz N. The Viral Etiology of Cervical Cancer. *Virus Res.* 2002;89(2):183-90.
29. Aldhafar AS, Alhulaybi AA, Khan TM. Knowledge, Early Signs and Symptoms, Risk Factors and Prevention of Cervical Cancer among Teachers in the Urban Schools in Al-Ahsa, Kingdom of Saudi Arabia. 2016;4(3):73-6.

30. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2017;28(4):iv72-iv83.
31. Obrzut B, Kusy M, Semczuk A, Obrzut M, Kluska J. Prediction of 5-Year Overall Survival in Cervical Cancer Patients Treated With Radical Hysterectomy Using Computational Intelligence Methods. *BMC Cancer*. 2017;17(1):1-9.
32. American Cancer Society. Survival Rates for Cervical Cancer, by Stage. 2017. <https://www.cancer.org/cancer/cervical-cancer/detection-diagnosis-staging/survival.html>.- Diakses Juni 2018.
33. S Elham, Yarandi F, Behtash N, Hemmatian O. Neoadjuvant Chemotherapy in Cervical Cancer : A Review Article. 2018;3(2):87-91.
34. He L, Wu L, Su G, Wei W, Liang L, Han L. The Efficacy of Neoadjuvant Chemotherapy in Different Histological Types Of Cervical Cancer. *Gynecol Oncol*. 2014.
35. Alcázar JL, Jurado M, Lopez-García G. Tumor Vascularization in Cervical Cancer by 3-Dimensional Power Doppler Angiography Correlation With Tumor Characteristics. *Int J Gynecol Cancer*. 2010;20(3):393-7.
36. Hapsari BK. Hubungan Antara Cell Death Dengan Vaskularisasi Dan Reaksi Limfosit Pada Kanker Serviks Jenis Squamous Cell Carcinoma. 2015;1(2):112-6.
37. Fuso L, Mazzola S, Marocco F, et al. Pretreatment Serum Hemoglobin Level as A Predictive Factor of Response To Neoadjuvant Chemotherapy in Patients With Locally Advanced Squamous Cervical Carcinoma : A Preliminary Report. 2005;99.
38. Cancer Society of Finland. Stages of cancer, differentiation and staging of cancer.2013.<https://www.allaboutcancer.fi/facts-about-cancer/stages/>.- Diakses Desember 2018.
39. Prandana DA, Rusda M. Pasien Kanker Serviks di RSUP H . Adam Malik Medan Tahun 2011. *E-Jurnal FK USU*. 2013;1(2):2011-4.
40. Haryani S, Defrin, Yenita. Artikel Penelitian Prevalensi Kanker Serviks Berdasarkan Paritas di RSUP Dr. M Djamil Padang Periode Januari 2011 - Desember 2012. 2014;5(3):647-52.
41. Herlana F, Nur IM, Purbaningsih W. Karakteristik Pasien Kanker Serviks berdasar atas Usia, Paritas, dan Gambaran Histopatologi di RSUD Al-Ihsan Bandung. 2017;1(22):138-42.
42. Nowakowski A, Cybulski M, Buda I, et al. Cervical Cancer Histology, Staging and Survival before and After Implementation of Organised Cervical Screening Programme in Poland. *Plos One*. 2016;11(5):1-10.

43. Ma Y, Zhao G, Qi J, et al. Neoadjuvant Brachytherapy and Chemotherapy Followed by Radical Surgery for Stage IB2 and IIA Cervical Cancer: A Retrospective Comparison with Chemoirradiation. *Mol Clin Oncol*. 2018;617-22.
44. Yang L, Guo J, Shen Y, et al. Clinical Efficacy and Safety of Paclitaxel Plus Carboplatin as Neoadjuvant Chemotherapy Prior to Radical Hysterectomy and Pelvic Lymphadenectomy for Stage IB 2 -IIB Cervical Cancer. 2015;8(8):13690-8.
45. Sardi JE, Giaroli A, Sananes C, et al. Long-Term Follow-up of the First Randomized Trial Using Neoadjuvant Chemotherapy in Stage Ib Squamous Carcinoma of the Cervix : The Final Results. 1997;69(67):61-9.
46. Gary L, Eddy MD, Manetta A, et al. Neoadjuvant Chemotherapy with Vincristine and Cisplatin Followed by Radical Hysterectomy and Pelvic Lymphadenectomy for FIGO Stage IB Bulky Cervical Cancer : A Gynecologic Oncology Group Pilot Study. *Gynecologic Oncology*. 1995;412-6.
47. Serur E, Mathews RP, Gates J, Levine P, Maiman M, Remy JC. Neoadjuvant Chemotherapy in Stage IB2 Squamous Cell Carcinoma of the Cervix. 1997;356(65):348-56.
48. Rustin G, Jones B, Dina R. Use of Neoadjuvant Chemotherapy Prior to Radical Hysterectomy in Cervical Cancer : Monitoring Tumour Shrinkage and Molecular Profile on Magnetic Resonance and Assessment of 3-Year Outcome Clinical. 2004;2:2326-31.
49. Taneja A, Rajaram S, Agarwal S, Singh KC, Sahni S, Goel N. "Quick Cycle" Neoadjuvant Chemotherapy in squamous cell carcinoma of cervix carcinoma. 2005;37(5):320-4.
50. Suprasert P, Thongsong T, Srisomboon J. Efficacy of Cisplatin in Early Stage Cervical Cancer with a Long Waiting Period for Surgery. 2007;8:51-4.